Beleodaq is a histone deacetylase (HDAC) inhibitor. HDACs catalyze the removal of acetyl groups from the
lysine residues of histones and some non-histone proteins. In vitro, belinostat caused the accumulation of
acetylated histones and other proteins, inducing cell cycle arrest and/or apoptosis of some transformed cells.
Belinostat shows preferential cytotoxicity towards tumor cells compared to normal cells. Belinostat inhibited
the enzymatic activity of histone deacetylases at nanomolar concentrations (